অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - simvastatin -

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - simvastatin -

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - simvastatin -

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methylprednisolone acetate, quantity: 40 mg/ml - injection, suspension - excipient ingredients: hydrochloric acid; macrogol 3350; miripirium chloride; sodium chloride; sodium hydroxide - indications as at 17 november 2004: a.for intramuscular administration. when oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of depo-nisolone is indicated as follows: 1. endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone acetate is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone acetate is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used). preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. congenital adrenal hyperplasia. hypercalcaemia associated with cancer. non-suppurative thyroiditis. 2. rheumatic disorders. as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: post-traumatic osteoarthritis. epicondylitis. synovitis of osteoarthritis. acute non-specific tenosynovitis. rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). acute gouty arthritis. psoriatic arthritis. ankylosing spondylitis. acute and subacute bursitis. 3. collagen diseases. during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus. acute rheumatic carditis. systemic dermatomyositis (polymyositis). 4. dermatological diseases. pemphigus. bullous dermatitis herpetiformis. severe erythema multiforme (stevens-johnson syndrome). severe seborrhoeic dermatitis. exfoliative dermatitis. severe psoriasis. mycosis fungoides. 5. allergic states. control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: bronchial asthma. drug hypersensitivity reactions. contact dermatitis.urticarial transfusion reactions. atopic dermatitis. acute non-infectious laryngeal oedema (adrenaline is the drug of first choice). serum sickness. 6. ophthalmic diseases. severe acute and chronic allergic and inflammatory processes involving the eye, such as: herpes zoster ophthalmicus. sympathetic ophthalmia. iritis, iridocyclitis. anterior segment inflammation. chorioretinitis. allergic conjunctivitis. diffuse posterior uveitis. allergic corneal marginal ulcers. optic neuritis. keratitis. 7. gastrointestinal diseases. to tide the patient over a critical period of the disease in: ulcerative colitis (systemic therapy). regional enteritis (systemic therapy). 8. respiratory diseases.symptomatic sarcoidosis. berylliosis. fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculous chemotherapy. aspiration pneumonitis. loeffler's syndrome not manageable by other means. 9. haematological disorders. acquired (autoimmune) haemolytic anaemia. erythroblastopenia (rbc anaemia). secondary thrombocytopenia in adults. congenital (erythroid) hypoplastic anaemia. 10. neoplastic diseases. for palliative management of: leukaemias and lymphomas in adults. acute leukaemia in childhood. 11. oedematous states. to induce diuresis or remission of proteinuria in the nephrotic syndrome without uraemia of the idiopathic type or that due to lupus erythematosus. 12. miscellaneous. tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy. trichinosis with neurological or myocardial involvement. b. for intra-articular or soft tissue administration depo-nisolone is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis. epicondylitis. rheumatoid arthritis. acute non-specific tenosynovitis. acute and subacute bursitis. post-traumatic osteoarthritis. acute gouty arthritis. c. for intralesional administration. depo-nisolone is indicated for intralesional use in the following conditions: keloids.discoid lupus erythematosus. necrobiosis lipoidica diabeticorum. alopecia areata. localised hypertrophic, infiltrated inflammatory lesions of licen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus (neurodermatitis). depo-nisolone may also be useful in cystic tumours of an aponeurosis or tendon (ganglia).

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - betamethasone acetate, quantity: 3 mg/ml (equivalent: betamethasone, qty 5.7 mg/ml); betamethasone sodium phosphate, quantity: 3.9 mg/ml - injection, suspension - excipient ingredients: disodium edetate; monobasic sodium phosphate; water for injections; dibasic sodium phosphate; benzalkonium chloride - celestone chronodose is indicated in the treatment of both severe and moderate conditions in acute and chronic self-limiting diseases responsive to systemic corticosteroid therapy and is especially useful in patients for whom treatment with oral corticosteroid medication is not feasible. representative conditions: rheumatic disorders: rheumatoid arthritis, acute and subacute bursitis, epicondylitis, acute non-specific tenosynovitis, myositis, fibrositis, tendonitis, psoriatic arthritis. collagen diseases: systemic lupus erythematosus, scleroderma, dermatomyositis. allergic states: status asthmaticus, chronic bronchial asthma, seasonal or perennial allergic rhinitis, severe allergic bronchitis, contact dermatitis, atopic dermatitis, hypersensitivity reactions to drug and insect bites. dermatologic conditions: localised, hypertrophic infiltrated lesions of lichen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus(neurodermatitis). keloids, discoid lupus erythematosus, necrobiosis lipoidi

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - celecoxib, quantity: 200 mg - capsule, hard - excipient ingredients: carrageenan; titanium dioxide; sodium lauryl sulfate; gelatin; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; iron oxide red; microcrystalline cellulose; iron oxide yellow; purified talc - for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,for the treatment of primary dysmenorrhoea in adults.,for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - celecoxib, quantity: 100 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; carrageenan; gelatin; magnesium stearate; sodium lauryl sulfate; lactose monohydrate; indigo carmine; titanium dioxide; purified talc; colloidal anhydrous silica - for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,for the treatment of primary dysmenorrhoea in adults.,for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - anagrelide hydrochloride, quantity: 0.57 mg (equivalent: anagrelide, qty 0.5 mg) - capsule, hard - excipient ingredients: povidone; magnesium stearate; gelatin; lactose monohydrate; croscarmellose sodium; titanium dioxide; microcrystalline cellulose; lactose - anagrelide lupin capsules are indicated for the treatment of essential thrombocythaemia

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tranexamic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; purified talc; colloidal anhydrous silica; povidone; vanillin; macrogol 8000; magnesium stearate; titanium dioxide; basic butylated methacrylate copolymer - oral administration hereditary angioneurotic oedema. short term use in the treatment of hyphaema and in patients with established coagulopathies who are undergoing minor surgery. menorrhagia.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tranexamic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; purified talc; croscarmellose sodium; vanillin; povidone; macrogol 8000; titanium dioxide; magnesium stearate; basic butylated methacrylate copolymer - oral administration hereditary angioneurotic oedema. short term use in the treatment of hyphaema and in patients with established coagulopathies who are undergoing minor surgery. menorrhagia.